



US008829038B2

(12) **United States Patent**
Donnelly

(10) **Patent No.:** **US 8,829,038 B2**
(45) **Date of Patent:** ***Sep. 9, 2014**

(54) **PARASITICIDAL FORMULATION**
(71) Applicant: **Fidopharm, Inc.**, Yardley, PA (US)
(72) Inventor: **Martin Benedict George Donnelly**,
Nottingham (GB)
(73) Assignee: **Velcera, Inc.**, Omaha, NE (US)
(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 80 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **13/852,513**

(22) Filed: **Mar. 28, 2013**

(65) **Prior Publication Data**

US 2013/0261162 A1 Oct. 3, 2013

Related U.S. Application Data

(63) Continuation of application No. 12/727,003, filed on
Mar. 18, 2010, now Pat. No. 8,580,837.

(60) Provisional application No. 61/161,361, filed on Mar.
18, 2009.

(51) **Int. Cl.**
A01N 25/02 (2006.01)
A01N 47/02 (2006.01)
A01N 49/00 (2006.01)
A01N 43/56 (2006.01)

(52) **U.S. Cl.**
CPC **A01N 25/02** (2013.01); **A01N 43/56**
(2013.01); **A01N 47/02** (2013.01); **A01N 49/00**
(2013.01)

USPC **514/404**

(58) **Field of Classification Search**
USPC 514/183
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,166,107 A 8/1979 Miller et al.
4,395,407 A 7/1983 Ballany et al.
4,607,050 A 8/1986 Kieran et al.
4,764,529 A 8/1988 Naik et al.
4,804,675 A 2/1989 Jensen-Korte et al.
4,973,589 A 11/1990 Barnett et al.
5,045,536 A 9/1991 Baker
5,053,227 A 10/1991 Chiang et al.
5,059,593 A 10/1991 Stendel et al.
5,120,716 A 6/1992 Miyazawa et al.
5,141,938 A 8/1992 Lindner et al.
5,192,787 A 3/1993 Bowers et al.
5,194,264 A 3/1993 Van Tonder
5,232,940 A 8/1993 Hatton et al.

5,256,679 A 10/1993 Minamida et al.
5,266,234 A 11/1993 Ho et al.
5,439,924 A 8/1995 Miller
5,468,765 A 11/1995 Banks et al.
5,482,956 A 1/1996 Lunkenheimer et al.
5,516,787 A 5/1996 Takada
5,567,429 A 10/1996 Senbo
5,612,047 A 3/1997 Duffy et al.
5,629,334 A 5/1997 Takada
5,777,075 A 7/1998 Scherkenbeck et al.
5,876,739 A 3/1999 Turnblad et al.
5,939,441 A 8/1999 Stetter et al.
6,010,710 A 1/2000 Etchegaray
6,096,329 A 8/2000 Jeannin
6,395,765 B1 5/2002 Etchegaray
6,426,333 B1 7/2002 Huet et al.
6,482,425 B1 11/2002 Huet et al.
6,565,450 B1 5/2003 Nakahara
6,673,836 B2 1/2004 Ramos
6,716,442 B2 4/2004 Hunter et al.
6,828,275 B2 12/2004 Uhr et al.
8,071,116 B2 12/2011 Sirinyan et al.
8,119,150 B2 2/2012 Tamarkin et al.
2002/0064547 A1 5/2002 Chern et al.
2002/0151577 A1 10/2002 Etchegaray
2003/0050327 A1 3/2003 Huet et al.
2003/0166688 A1 9/2003 Soll et al.
2004/0167175 A1 8/2004 Soll et al.
2004/0198676 A1 10/2004 Soll et al.
2005/0192319 A1 9/2005 Boeckh et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA 1069823 1/1980
CN 101288409 A 10/2008

(Continued)

OTHER PUBLICATIONS

Donahue, W. A., Jr. et al., "Evaluating a synergized pyrethrin/(S)-
methoprene spray against feline flea infestations," *Veterinary Medi-*
cine, pp. 999-1007 (1992).

(Continued)

Primary Examiner — Jeffrey S. Lundgren

Assistant Examiner — Zenab Olabowale

(74) *Attorney, Agent, or Firm* — Polsinelli PC

(57) **ABSTRACT**

The present invention provides a parasiticidal formulation comprising: Fipronil, or a veterinarily acceptable derivative thereof; at least one C₁-C₆ alcohol co-solvent, wherein the total amount of C₁-C₆ alcohol is up to 8% by weight of the formulation; at least one organic solvent which is not the C₁-C₆ alcohol co-solvent; and at least one crystallization inhibitor, wherein the total amount of crystallization inhibitor is from 2 to 20% by weight of the formulation. The formulations of the invention have higher flash points than known parasiticidal formulations comprising Fipronil and therefore provide safer formulations for use in the home, storage, manufacture and distribution.

21 Claims, No Drawings

(56)

References Cited

U.S. PATENT DOCUMENTS

2008/0003282 A1 1/2008 Soll et al.
 2010/0125097 A1 5/2010 Soll et al.
 2012/0029043 A1 2/2012 Derrieu

FOREIGN PATENT DOCUMENTS

CN	101352168	A	1/2009
EP	0051786	A1	5/1982
EP	0137627	A2	4/1985
EP	0045424	B1	6/1985
EP	0120286	B1	7/1987
EP	0234119	A1	9/1987
EP	0271923	A1	6/1988
EP	0295117	A1	12/1988
EP	0432494	A2	6/1991
EP	0500209	A1	8/1992
EP	0516590	A1	12/1992
EP	0234119	B1	8/1994
EP	0682869	A1	11/1995
EP	0295117	B1	4/2000
EP	1449435	A1	8/2004
EP	0682869	B1	12/2005
EP	1130966	B2	5/2009
EP	1484033	B1	2/2011
FR	2713889		12/1994
GB	2334888	A	9/1999
JP	4-235104	A	8/1992
JP	6-65219		3/1994
JP	7-179307		7/1995
NZ	567277		4/2008
WO	WO 87/03781		7/1987
WO	WO 90/09738		9/1990
WO	WO 91/13545		9/1991
WO	WO 93/02058		2/1993
WO	WO 93/06089		4/1993
WO	WO 93/18010		9/1993
WO	WO 93/20799		10/1993
WO	WO 94/21606		9/1994
WO	WO 94/26113		11/1994
WO	WO 95/04746		2/1995
WO	WO 95/33380		12/1995
WO	WO 96/16544		6/1996
WO	WO 98/25466		6/1998
WO	WO 00/62610		10/2000
WO	WO 01/40446		6/2001
WO	WO 2005/074912		8/2005
WO	WO 2007/018659		2/2007
WO	WO 2010/026370		3/2010
WO	WO 2010/092355		8/2010
WO	WO 2010/106325		9/2010
ZA	884179		6/1988

OTHER PUBLICATIONS

Summary of Product Characteristics, "Frontline Combo Spot-On Dog M," AN2218/2007 (Jul. 2, 2008).

Frontline Spray Brochure, "Frontline No Other Flea Treatment Works Like It or Lasts Like It," (Mar. 1996).

Dictionnaire Medicaments Veterinaires, 14th edition, pp. 1083, Wolters Kluwer, France (2007).

Dictionnaire Medicaments Veterinaires, 14th edition, pp. 638-639, Wolters Kluwer, France (2007).

Postal, J.-M. R. et al., "Field Efficacy of a Mechanical Pump Spray Formulation Containing 0.25% Fipronil in the Treatment and Control of Flea Infestation and Associated Dermatological Signs in Dogs and Cats," *Veterinary Dermatology*, 6(3):153-158 (1995).

Olsen, A., "Ovicidal effect on the cat flea, *Ctenocephalides felis* (bouche), of treating fur of cats and dogs with methoprene," *International Pest Control*, pp. 10-14 (1985).

Garg, R. C. et al., "Pharmacologic profile of methoprene, an insect growth regulator, in cattle, dogs and cats," *Topics in Drug Therapy, Journal of the American Veterinary Medical Association*, 194(3): 410-412 (1989).

Walters, K. A., "Mechanisms and Prediction of Nonionic Surfactant Effects on Skin Permeability," In: *Pharmaceutical Skin Penetration Enhancement*, Walters, K. A. et al., (eds.), Marcel Dekker, Inc., New York, Chapter 5: pp. 113-116, 129-131, 136-139; Chapter 10: pp. 229-242; Chapter 11: pp. 243-267; and Chapter 16: pp. 345-364 (1993).

Summary of Product Characteristics for Vet Kem Dog Spray, date of approval: Apr. 2003.

Fraser, C. M. et al. (eds.), *The Merck Veterinary Manual*, Seventh Edition, Merck & Co., Inc., Rahway, NJ, pp. 796-797, 1497-1502 (1991).

Tomlin, C. (ed.), *The Pesticide Manual, Incorporating the Agrochemicals Handbook*, Tenth Edition, The British Crop Protection Council, Surrey, The United Kingdom and The Royal Society of Chemistry, Cambridge, The United Kingdom, Foreword and pp. 296, 297, 463, 591-593, 680-682, 860 and 861 (1994).

Jeannin, Ph. et al., "Fipronil: a new insecticide for flea control," *Proceedings of the British Small Animal Veterinary Association Congress*, Birmingham; B.S.A.V.A., p. 174 (1994).

Panchagnula, R. et al., "Development and evaluation of an intracutaneous depot formulation of corticosteroids using transcutol as a cosolvent: in-vitro, ex-vivo and in-vivo rat studies," *J. Pharm. Pharmacol.*, 43:609-614 (1991).

Hardin, B. D. et al., "Developmental toxicity of four glycol ethers applied cutaneously to rats," *Environmental Health Perspectives*, 57:69-74 (1984).

Chiang, C-M et al., "Bioavailability assessment of topical delivery systems: effect of vehicle evaporation upon in vitro delivery of minoxidil from solution formulations," *International Journal of Pharmaceutics*, 55:229-236 (1989).

Hadgraft, J. et al., "Skin penetration enhancement," *Journal of Dermatological Treatment*, 5:43-47 (1994).

Pellett, M. A. et al., "Effect of supersaturation on membrane transport: 2. piroxicam," *International Journal of Pharmaceutics*, 111:1-6 (1994).

Grasso, P. et al., "Methods of measuring, and factors affecting, percutaneous adsorption," *J. Soc. Cosmet. Chem.*, 23:481-521 (1972).

Lauer, A. C. et al., "Transfollicular Drug Delivery," *Pharmaceutical Research*, 12(2):179-186 (1995).

Illel, B. et al., "Follicles Play an Important Role in Percutaneous Adsorption," *Journal of Pharmaceutical Sciences*, 80(5):424-427 (1991).

Hueber, F. et al., "Role of Transepidermal and Transfollicular Routes in Percutaneous Adsorption of Steroids: In Vitro Studies on Human Skin," *Skin Pharmacol.*, 7:237-244 (1994).

Coldman, M. F. et al., "Enhancement of Percutaneous Adsorption by the Use of Volatile: Nonvolatile Systems as Vehicles," *Journal of Pharmaceutical Sciences*, 58(9):1098-1102 (1969).

Research Disclosure, "Extended Efficacy Spectrum of Azole Pesticides," No. 380, p. 802 (Dec. 1, 1995).

Uk, S., *Eur. J. Plant Pathol.*, 101(1):8 (1995).

Genchi, C. et al., "Efficacia del Fipronil in Formulazione Spray (Frontline RM) Nel Trattamento Delle Infestazioni da Pulci e da Zecche nel Cane, Professione Veterinaria, No. i., Supplement, pp. 19-22 (1995).

Postal, J. M. et al., "Efficacia di una formulazione spray a base di fipronil allo 0.25% nel trattamento e nella prevenzione delle infestazioni da pulci nel cane e nel gatto," *Proffisione Veterinaria*, 1:17-18 (1995).

Atwell, R. et al., "The Effects of Fipronil on Ixodes Holocyclus on Dogs in Northern NSW," *Aust. Vet. Pract.* 26(3):155 (1996) abstract. Cooper, P. R. et al., "Use of fipronil to eliminate recurrent infestation by *Trichodectes canis* in a pack of bloodhounds," *The Veterinary Record*, 139(4):95 (1996).

Postal, et al., "Efficacy of a 0.25% fipronil based formulation spray in the treatment and prevention of flea infestations of dogs and cats," *CABA* pp. 17-18 (1900) machine translation attached.

Freedom of Information Summary, NADA 141-026, Trade Name: Program Suspension, Sponsor: Ciba Animal Health, Ciba-Geigy Corporation, Approval Date: Mar. 28, 1995.

Freedom of Information Summary, NADA 141-035, Trade Name: Program Tablets, Sponsor: Ciba Animal Health, Ciba-Geigy Corporation, Approval Date: Nov. 23, 1994.

(56)

References Cited

OTHER PUBLICATIONS

Kegley, S. et al., PAN Pesticides Database—Pesticide Products, Product Name on Label: Ovitrol plus ii flea, tick and bot spray, Pesticide Action Network, North America, San Francisco, CA (2007).

Kegley, S. et al., PAN Pesticides Database—Pesticide Products, Product Name on Label: Ovitrol plus complete flea collar for cats and kittens, Pesticide Action Network, North America, San Francisco, CA (2007).

Young, D. R. et al., "Efficacy of fipronil/(S)-methoprene combination spot-on for dogs against shed eggs, emerging and existing adult cat fleas (*Ctenocephalides felis*, Bouche)," *Veterinary Parasitology*, 125:397-407 (2004).

"Frontline Combo Spot-On Cat," 7 pages, (issued Jan. 29, 2004, revised Dec. 2011).

"Frontline Combo Spot-On Dog M," 6 pages, (issued Jan. 29, 2004, revised May 2011).

"Frontline Spot on Dog 10% w/v Spot on Solution," 7 pages, (first authorized Nov. 27, 2006, revised Mar. 2010).

"Frontline Spot on Cat 10% w/v Spot on Solution," 6 pages, (first authorized Nov. 27, 2006, revised May 2010).

Jacobson et al., "The ability of fipronil to prevent transmission of *Borrelia burgdorferi*, the causative agent of Lyme disease in dogs" *The Journal of Applied Research in Veterinary Medicine*, 29(1):39-45, 2004.

Otranto et al., "Efficacy of a combination of imidacloprid 10%/permethrin 50% versus fipronil 10%/(s)-methoprene 12%, against ticks in naturally infected dogs" *Veterinary Pathology*, 130:293-304, 2005.

Ding, Jie, et al., "Evaluation of Ehtoxynonalfourbutane as a safe and environmentally friendly solvent for chiral normal-phase LC-atmospheric pressure chemical ionization/electrospray ionization-mass spectrometry", *Journal of chromatography*, 2005, 1076(1-2), 34-43.

Wang, Peng, et al., "Chiral resolution of malathion and fipronil on the amylose derivative chiral stationary phase," *Yingong Huaxue*, 2006, 23(10), 1170-1172. (English abstract only).

Wang, Peng et al., "Effects of alcohols and temperature on the direct chiral resolutions of fipronil, isocarbophos and carfentrazone e-ethyl," *Biomedical Chromatography*, 2003, 19(6), 454-458.

Ying, Guang-Guo, et al., "Sorption of Fipronil and its metabolites on soils from South Australia," *Journal of Environmental Science and Health, Part B: Pesticides, Food Contaminants, and Agricultural Wastes*, 2001.

PARASITICIDAL FORMULATION**CROSS REFERENCE TO RELATED APPLICATION**

This application is a continuation of U.S. patent Ser. No. 12/727,003, filed Mar. 18, 2010, which claims priority to U.S. Provisional Application No. 61/161,361, filed Mar. 18, 2009, the disclosures of which are herein incorporated by reference for all purposes.

TECHNICAL FIELD

This invention relates to a parasitocidal formulation comprising Fipronil, or a veterinarily acceptable derivative thereof. In particular, it relates to parasitocidal formulations comprising Fipronil having improved safety characteristics compared with known Fipronil formulations.

BACKGROUND ART

EP 295 217 A and EP 352 944 A describe a class of 1-N-arylpyrazole-based insecticides. A particular compound of this class is 5-amino-1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-4-((trifluoromethyl)sulfinyl)-1H-pyrazole-3-carbonitrile, also known as Fipronil. Fipronil has proven to be particularly effective as a parasiticide against crop parasites and against mammal ectoparasites, in particular fleas, ticks, flies and myiases.

Fipronil formulations are disclosed in GB 2 331 242 A, which also discloses the combination of Fipronil with other parasitocides. Furthermore, GB 2 317 264 A discloses Fipronil formulations additionally comprising an IGR (insect growth regulator) compound, e.g. Methoprene.

Parasitocidal formulations comprising Fipronil are marketed for use in the home treatment of domestic pets, e.g. cats and dogs. One such formulation is FRONTLINE® PLUS FOR DOGS.

However, a problem with these known formulations is their relatively low flashpoints, i.e. the lowest temperatures at which they can form an ignitable mixture in air. The Material Safety Data Sheet for the FRONTLINE® PLUS FOR DOGS formulation indicates the flashpoint for this formulation to be 36° C. (97° F.).

A liquid which forms an ignitable mixture at 36° C. presents a safety risk during use in the home, and during manufacture, distribution and storage, because temperatures in many countries exceed this level during summer. There is therefore a need for effective parasitocidal formulations comprising Fipronil which have higher flashpoints, and therefore improved safety profiles, but which still retain parasitocidal efficacy.

Accordingly, the object of the present invention is to provide a parasitocidal formulation comprising Fipronil having improved safety while maintaining parasitocidal efficacy.

DISCLOSURE OF THE INVENTION

The present invention provides a parasitocidal formulation comprising:

- Fipronil, or a veterinarily acceptable derivative thereof;
- at least one C₁-C₆ alcohol co-solvent, wherein the total amount of C₁-C₆ alcohol is up to 8% by weight of the formulation;
- at least one organic solvent which is not the C₁-C₆ alcohol co-solvent; and at least one crystallisation inhibitor,

wherein the total amount of crystallisation inhibitor is from 2 to 20% by weight of the formulation.

The parasitocidal formulations of the present invention surprisingly have a flashpoint of greater than 36° C. (97° F.). In particular, formulations of the present invention have been shown to have flashpoints between 47° C. and 52° C. and are therefore safer than the known formulations of the prior art. The formulations of the present invention also retain parasitocidal efficacy.

The present invention further provides the use of a formulation according to the present invention as a parasiticide, particularly for controlling parasites on a mammal (e.g. a cat or a dog) in need thereof.

The present invention further provides a process for controlling parasites on mammals in need thereof, in particular cats and dogs, said process comprising treating the mammal by application to the skin of a parasitocidally effective dose of a formulation according to the present invention.

EMBODIMENTS OF THE INVENTION

In one embodiment, the amount of Fipronil, or a veterinarily acceptable derivative thereof, in the formulation is from 5% to 20%, alternatively from 5% to 15%, alternatively from 8% to 12%, alternatively about 10% by weight of the formulation.

The term “veterinarily acceptable derivative” of Fipronil includes any veterinarily acceptable salt, solvate or hydrate of Fipronil. The term “veterinarily acceptable salt” includes a salt prepared from veterinarily acceptable non-toxic acids or bases including inorganic or organic acids and bases.

In one embodiment, the formulation of the present invention comprises an IGR (insect growth regulator) compound, e.g. S-Methoprene. In one embodiment, the amount of S-Methoprene in the formulation is from 5% to 25%, alternatively from 5% to 20%, alternatively from 5% to 15%, alternatively from 8% to 12% by weight of the formulation.

The amount of the at least one C₁-C₆ alcohol co-solvent in the formulation is up to 8% by weight of the formulation. In one embodiment, the amount of at least one C₁-C₆ alcohol co-solvent in the formulation is from 2% to 8%, alternatively about 5% by weight of the formulation.

Examples of the C₁ to C₆ alcohol co-solvent are methanol, ethanol, propanol, isopropanol or butanol, and combinations thereof. In one embodiment, the C₁ to C₆ alcohol is ethanol.

In one embodiment, the formulation comprises at least one antioxidant. In one embodiment, the amount of antioxidant in the formulation is from 0.005 to 1%, alternatively from 0.01 to 0.05%, alternatively from 0.02 to 0.03%, alternatively about 0.03% by weight of the formulation.

Examples of the antioxidant are butylated hydroxylanisole, butylated hydroxytoluene, alpha tocopheral, ascorbic acid, ascorbyl palmitate, fumaric acid, malic acid, citric acid, sodium ascorbate, sodium metabisulfate, n-propyl gallate, monoethioglycerol and combinations thereof. In one embodiment, the antioxidant is butylated hydroxylanisole, butylated hydroxytoluene or combinations thereof. In one embodiment, the at least one antioxidant consists of butylated hydroxylanisole (e.g. in amount of about 0.02% by weight) and butylated hydroxytoluene (e.g. in amount of 0.01% by weight).

The amount of the at least one crystallisation inhibitor in the formulation is from 2 to 20% by weight of the formulation. In one embodiment, the amount of crystallisation inhibitor in the formulation is from 4% to 15%, alternatively 6% to 12%, alternatively about 10% by weight of the formulation.

The at least one crystallization inhibitor satisfies the following test having steps (i)-(iii): (i) 0.5 ml of a formulation of the invention comprising the at least one crystallisation inhibitor in an amount of 10% by weight is deposited in an open Petri dish at 20° C.; (ii) the deposited formulation is observed at 20 minute intervals; and (iii) no crystals are observed with the naked eye within 3 hours of depositing the formulation.

Examples of the crystallization inhibitor are polyvinylpyrrolidone, polyvinyl alcohols, copolymers of vinyl acetate and vinylpyrrolidone, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol, polyoxyethylenated sorbitan esters, polyoxyethylenated hydrogenated castor oil (e.g. PEG-60 hydrogenated castor oil), lecithin, sodium carboxymethylcellulose, or acrylic derivatives such as methacrylates.

Alternatively, or in addition, the crystallization inhibitor may be an anionic surfactant such as alkaline stearates, in particular sodium, potassium or ammonium stearate; calcium stearate; triethanolamine stearate; sodium abietate; alkyl sulphates, in particular sodium lauryl sulphate and sodium cetyl sulphate; sodium dodecylbenzenesulphonate, sodium dioctylsulphosuccinate; fatty acids, in particular those derived from coconut oil.

Alternatively, or in addition, the crystallization inhibitor may be a cationic surfactant such as water-soluble quaternary ammonium salts such as cetyltrimethylammonium bromide, octadecylamine hydrochloride.

Alternatively, or in addition, the crystallization inhibitor may be a nonionic surfactant such as polyoxyethylenated sorbitan esters, in particular polysorbate 80, polyoxyethylenated alkyl ethers; polyethylene glycol stearate, polyoxyethylenated derivatives of castor oil, polyglycerol esters, polyoxyethylenated fatty alcohols, polyoxyethylenated fatty acids, copolymers of ethylene oxide and propylene oxide.

Alternatively or in addition, the crystallization inhibitor may be an amphoteric surfactant such as a substituted lauryl compound of betaine.

In one embodiment, the at least one crystallization inhibitor is polyethylene glycol (e.g. polyethylene glycol 1000), polyethylene glycol hydrogenated castor oil (e.g. polyethylene glycol 60 hydrogenated castor oil, e.g. Nikkol HCO 60), or combinations thereof.

In one embodiment, the at least one crystallisation inhibitor consists of two crystallisation inhibitors.

In one embodiment, the at least one crystallization inhibitor is polyethylene glycol (e.g. polyethylene glycol 1000) and polyethylene glycol hydrogenated castor oil (e.g. polyethylene glycol 60 hydrogenated castor oil, e.g. Nikkol HCO 60). In one embodiment, the amount of polyethylene glycol is about 5% by weight of the formulation and the amount of polyethylene glycol hydrogenated castor oil is about 5% by weight of the formulation.

As used herein, "polyethylene glycol" includes combinations of polyethylene glycols having different molecular weights.

The formulation of the invention comprises at least one organic solvent which is not C₁-C₆ alcohol. Typically, the total amount of the at least one organic solvent which is not C₁-C₆ alcohol makes up the balance of the formulation. Examples of the at least one organic solvent which is not C₁-C₆ alcohol are diethylene glycol monoethyl ether, ethylene glycol monoethyl ether, dipropylene glycol n-butyl ether, dipropylene glycol monomethyl ether, or combinations thereof. In one embodiment, the at least one organic solvent which is not C₁-C₆ alcohol is diethylene glycol monoethyl ether (e.g. Transcutol P).

In one embodiment, the formulation of the present invention consists of:

9.7 wt % Fipronil;
5.0 wt % ethanol;
0.02 wt % butylated hydroxyanisole;
0.01 wt % butylated hydroxytoluene;
5.0 wt % polyethylene glycol 1000;
5.0 wt % polyethylene glycol 60 hydrogenated castor oil;
balance diethylene glycol monoethyl ether.

In another embodiment, the formulation of the present invention consists of

9.8 wt % Fipronil;
11.8 wt % S-Methoprene;
5.0 wt % ethanol;
0.02 wt % butylated hydroxyanisole;
0.01 wt % butylated hydroxytoluene;
5.0 wt % polyethylene glycol 1000;
5.0 wt % polyethylene glycol 60 hydrogenated castor oil;
balance diethylene glycol monoethyl ether.

This formulation is particularly suitable for cats.

In another embodiment, the formulation of the present invention consists of

9.8 wt % Fipronil;
8.8 wt % S-Methoprene;
5.0 wt % ethanol;
0.02 wt % butylated hydroxyanisole;
0.01 wt % butylated hydroxytoluene;
5.0 wt % polyethylene glycol 1000;
5.0 wt % polyethylene glycol 60 hydrogenated castor oil;
balance diethylene glycol monoethyl ether.

This formulation is particularly suitable for dogs.

The formulations of the present invention may be manufactured by mixing the desired components in the desired amounts.

The formulations of the present invention are intended for mammals, in particular cats and dogs, and are generally deposited onto the skin ("spot-on" or "pour-on" application). The deposition is generally a localised application over a surface area of less than 10 cm², especially of between 5 and 10 cm², in particular at one point or two points which may be located between the mammal's shoulders. Once deposited, the formulation diffuses over the mammal's body and dries without crystallising or modifying the appearance or feel of the fur.

As mentioned above, the present invention provides a process for controlling parasites on mammals, in particular cats and dogs, said process comprising treating the mammal by application to the skin of parasiticidally effective doses of a formulation according to the present invention.

The object of the application of the formulations of the present invention may be non-therapeutic in that it relates to the cleaning of mammal hairs and skin by elimination of parasites, as well as their residues and dejections. The treated mammals will therefore have hair which is more pleasant to look at and feel.

The object of the application of the formulations of the present invention may be therapeutic if the intention is to treat and prevent parasitoses having pathologic consequences.

The process of the present invention may treat the mammal by local point application to the skin of "spot-on" type. Spot-on formulations are particularly advantageous due to their efficacy, their speed of action and the pleasant appearance of the mammal's fur after application and drying.

The process, formulations and use of the present invention is particularly suitable when the parasites are ectoparasites, in particular ticks or fleas.

5

Treatment of mammals, in particular cats and dogs, with the formulation of the present invention may be carried out every two or three months.

The treatment may be carried out so as to administer to the mammal a dose from 0.1 to 80 mg/kg, alternatively from 1 to 40 mg/kg, alternatively from 1 to 30 mg/kg of the parasitocidal component, wherein the parasitocidal component is either Fipronil or the combination of Fipronil and S-Methoprene when S-Methoprene is present.

It is to be understood that these dosage values are average values which may vary because the formulation will be administered to mammals having relatively different body weights. Consequently, the doses applied may be smaller or larger than the doses provided above.

MODES FOR CARRYING OUT THE INVENTION

The invention is further illustrated by the following examples. It will be appreciated that the examples are for illustrative purposes only and are not intended to limit the invention as described above. Modification of detail may be made without departing from the scope of the invention.

Example 1

A formulation of the following composition is prepared by mixing ingredients in the following amounts:

9.7 wt % Fipronil;
5.0 wt % ethanol;
0.02 wt % butylated hydroxyanisole;
0.01 wt % butylated hydroxytoluene;
5.0 wt % polyethylene glycol 1000;
5.0 wt % polyethylene glycol 60 hydrogenated castor oil (Nikkol HCO 60);
balance diethylene glycol monoethyl ether (Transcutol P).

Example 2

A formulation of the following composition particularly useful for cats is prepared by mixing ingredients in the following amounts:

9.8 wt % Fipronil;
11.8 wt % S-Methoprene;
5.0 wt % ethanol;
0.02 wt % butylated hydroxyanisole;
0.01 wt % butylated hydroxytoluene;
5.0 wt % polyethylene glycol 1000;
5.0 wt % polyethylene glycol 60 hydrogenated castor oil (Nikkol HCO 60);
balance diethylene glycol monoethyl ether (Transcutol P).

Example 3

A formulation of the following composition particularly useful for dogs is prepared by mixing ingredients in the following amounts:

9.8 wt % Fipronil;
8.8 wt % S-Methoprene;
5.0 wt % ethanol;
0.02 wt % butylated hydroxyanisole;
0.01 wt % butylated hydroxytoluene;
5.0 wt % polyethylene glycol 1000;
5.0 wt % polyethylene glycol 60 hydrogenated castor oil (Nikkol HCO 60);
balance diethylene glycol monoethyl ether (Transcutol P).

6

Example 4

Flash Points

The flashpoints of the compositions of Examples 1-3 were measured and were found to be between 47-52° C., some 11-18° C. higher than the flashpoint of the marketed product FRONTLINE® PLUS FOR DOGS.

The formulations of the invention therefore have a reduced propensity to form ignitable mixtures with air. They therefore provide a safer formulation for use, storage, distribution and manufacture.

Example 5

Parasitocidal Activity

The compositions of Examples 1-3 have been shown in trials to have parasitocidal activity.

The invention claimed is:

1. A parasitocidal formulation comprising:

from about 8 to about 12% by weight Fipronil, or a veterinary acceptable derivative thereof; less than about 5% by weight of the formulation of ethanol; and

at least one organic solvent which is not ethanol.

2. The formulation of claim 1, further comprising one or more crystallization inhibitor.

3. The formulation of claim 1, wherein the Fipronil or a veterinarily acceptable derivative thereof is Fipronil.

4. The formulation of claim 1, which further comprises an insect growth regulator (IGR).

5. The formulation of claim 4, wherein the IGR is s-methoprene.

6. The formulation of claim 5 wherein the amount of S-methoprene is from about 5% to about 25% by weight of the formulation.

7. The formulation of claim 1 wherein the at least one organic solvent which is not ethanol is diethylene glycol monoethyl ether, ethylene glycol monoethyl ether, dipropylene glycol n-butyl ether, dipropylene glycol monomethyl ether, or combinations thereof.

8. The formulation of claim 7 wherein the at least one organic solvent which is not ethanol is diethylene glycol monoethyl ether.

9. The formulation of claim 1 further comprising at least one antioxidant.

10. The formulation of claim 9 comprising at least two antioxidants.

11. The formulation of claim 9 wherein the at least one antioxidant is selected from the group consisting of butylated hydroxyanisole, butylated hydroxytoluene, alpha tocopheral, ascorbic acid, ascobyl palmitate, fumaric acid, malic acid, citric acid, sodium ascorbate, sodium metabisulfate, n-propyl gallate, and monoethioglycerol.

12. The formulation of claim 10 wherein the at least two antioxidants are independently selected from the group consisting of butylated hydroxyanisole, butylated hydroxytoluene, alpha tocopheral, ascorbic acid, ascobyl palmitate, fumaric acid, malic acid, citric acid, sodium ascorbate, sodium metabisulfate, n-propyl gallate, and monoethioglycerol.

13. The formulation of claim 11 wherein the at least one antioxidant is butylated hydroxyanisole or butylated hydroxytoluene.

14. The formulation of claim 13 wherein the at least one antioxidant is butylated hydroxyanisole.

15. The formulation of claim 13 wherein the at least one antioxidant is butylated hydroxytoluene.

16. The formulation of claim **12** wherein the at least two antioxidants are butylated hydroxytoluene and butylated hydroxyanisole.

17. The formulation of claim **1**, wherein the formulation is formulated for spot-on delivery. 5

18. The formulation of claim **2**, wherein the one or more crystallization inhibitors is selected from the group consisting of polyethylene glycols, polyethylene glycol hydrogenated castor oil, polyvinylpyrrolidone, polyvinyl alcohols, copolymers of vinyl acetate, vinylpyrrolidone, benzyl alcohol, man- 10
nitol, glycerol, sorbitol, polyoxyethylenated sorbitan esters, polyoxyethylenated hydrogenated castor oil, lecithin, sodium carboxymethylcellulose, methacrylates and combinations thereof.

19. The formulation of claim **18** wherein the at least one 15
crystallization inhibitor is polyethylene glycols, polyethylene glycol hydrogenated castor oil, or combinations thereof.

20. The formulation of claim **19** wherein the at least one crystallization inhibitor is polyethylene glycols and polyeth- 20
ylene glycol hydrogenated castor oil.

21. The formulation of claim **20** wherein the amount of polyethylene glycol is about 5% by weight of the formulation and the amount of polyethylene glycol hydrogenated castor oil is about 5% by weight of the formulation.

* * * * *

25